Incorporating digitally derived endpoints within clinical development programs by leveraging prior work.

Autor:	Bertha A; Bayer, 801 Pennsylvania Ave NW, Washington, DC, 20004, USA. amy.bertha@bayer.com., Alaj R; Regeneron, Terrytown, NJ, USA., Bousnina I; Genentech, South San Francisco, CA, USA., Doyle MK; Amgen, Thousand Oaks, CA, USA., Friend D; Janssen, Raritan, NJ, USA., Kalamegham R; Genentech, South San Francisco, CA, USA., Oliva L; Biogen, Cambridge, MA, USA., Knezevic I; Bayer, Wuppertal, Germany., Kramer F; Bayer, Wuppertal, Germany., Podhaisky HP; Bayer, Berlin, Germany., Reimann S; Bayer, Wuppertal, Germany.
Jazyk:	angličtina
Zdroj:	NPJ digital medicine [NPJ Digit Med] 2023 Aug 10; Vol. 6 (1), pp. 139. Date of Electronic Publication: 2023 Aug 10.
DOI:	10.1038/s41746-023-00886-9
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink